The responses, guidance, and advisories provided by the Pharmaceutical Advertising Advisory Board (PAAB),
including but not limited to those available through the PAAB Forum, the PAAB website, and any PAAB
correspondences, are specifically intended to assist individuals navigating the PAAB preclearance system.
Repurposing or reproducing this content without written consent from the PAAB Commissioner is strictly
prohibited. This prohibition includes, but is not limited to, use in machine learning or AI models.
Future Service - Accelerated Preclearance Pathway
-
Hello @manufacturer @agency
The PAAB is excited to reveal our plan to launch a new service that’s intended to reduce the time for submission approvals.
With a view to launch a pilot later in the year, the Accelerated Preclearance Pathway (APP) will complement the existing preclearance pathway currently in place.
At this early stage, we’d like to invite you to comment on the proposed new service via the link below. Here, you’ll be able to learn more about the service and provide feedback.
Please check out www.paabfeedback.ca to learn more and for the opportunity to comment. Commenting will close on April the 14th, so do not delay in providing your feedback.
Please feel free to post any questions in the comments below.
